Home ›
NPI 1326430091
NPI deactivated
1326430091
1326430091 was paid $46K by Medicaid between Jan 2018 and Jan 2020, across 39 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 20% of everything it billed.
33Billing provider info1326430091
33aNPI1326430091
33bProvider type—
28Total paid$46K
24GClaims81,573
24DCodes billed39
24AFirst – last monthJan 2018 – Jan 2020
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,153 | $12K | |
| 2019 | 72,953 | $28K | |
| 2020 | 6,467 | $7K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 20% | 1,216 | 906 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.9% | 1,098 | 908 | $4K |
| 80347 | 4.4% | 3,099 | 1,886 | $2K | |
| 80321 | 4.2% | 3,060 | 1,859 | $2K | |
| 80361 | 3.9% | 3,140 | 1,916 | $2K | |
| 80364 | 3.6% | 3,044 | 1,866 | $2K | |
| 80372 | 3.5% | 3,125 | 1,903 | $2K | |
| 80355 | 3.3% | 3,012 | 1,795 | $2K | |
| 80373 | 3.1% | 2,869 | 1,767 | $1K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 2.8% | 12 | 12 | $1K |
| 80366 | 2.7% | 2,732 | 1,641 | $1K | |
| 80337 | 2.6% | 2,683 | 1,593 | $1K |
27 more codes
| 80367 | 2.6% | 2,700 | $1K | |
| 80332 | 2.6% | 2,708 | $1K | |
| 80370 | 2.6% | 2,702 | $1K | |
| 83992 | 2.6% | 2,975 | $1K | |
| 80345 | 2.3% | 3,000 | $1K | |
| 80349 | 2.3% | 3,151 | $1K | |
| 80365 | 2.3% | 3,149 | $1K | |
| 80354 | 2.3% | 3,152 | $1K | |
| 80359 | 2.3% | 3,002 | $1K | |
| 80356 | 2.3% | 3,125 | $1K | |
| 80325 | 2.2% | 3,073 | $1K | |
| 80353 | 2.1% | 3,142 | $997.32 | |
| 80348 | 2.1% | 3,147 | $979.32 | |
| 80360 | 2.1% | 2,984 | $968.71 | |
| 80358 | 2.0% | 3,008 | $922.63 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 318 | $375.89 |
| 82570 | <1% | 3,109 | $352.29 | |
| 81003 | <1% | 3,108 | $162.76 | |
| 80369 | <1% | 36 | $117.53 | |
| 80371 | <1% | 261 | $111.41 | |
| 80351 | <1% | 263 | $111.41 | |
| 80338 | <1% | 13 | $75.06 | |
| 80363 | 0% | 72 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 224 | $0.00 |
| 80324 | 0% | 20 | $0.00 | |
| 80346 | 0% | 23 | $0.00 | |
| 80336 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.